MXPA04000124A - Composicion farmaceutica para la terapia de cistitis intersticial. - Google Patents

Composicion farmaceutica para la terapia de cistitis intersticial.

Info

Publication number
MXPA04000124A
MXPA04000124A MXPA04000124A MXPA04000124A MXPA04000124A MX PA04000124 A MXPA04000124 A MX PA04000124A MX PA04000124 A MXPA04000124 A MX PA04000124A MX PA04000124 A MXPA04000124 A MX PA04000124A MX PA04000124 A MXPA04000124 A MX PA04000124A
Authority
MX
Mexico
Prior art keywords
interstitial cystitis
treatment
medicinal composition
hypersthesia
quinuclidine
Prior art date
Application number
MXPA04000124A
Other languages
English (en)
Inventor
Takeuchi Makoto
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of MXPA04000124A publication Critical patent/MXPA04000124A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Se describe un depresor del nervio sensorial sensible a la capsaicina, que contiene 1-fenil-1,2,3,4-tetrahidroisoquinolin-2-carboxilato de quinuclidin-3-ilo o una sal del mismo como ingrediente activo, especificamente un medicamento terapeutico de cistitis intersticial, trastorno hipersensible del sistema urinario inferior y/o prostatitis abacteriana.
MXPA04000124A 2001-07-10 2002-07-08 Composicion farmaceutica para la terapia de cistitis intersticial. MXPA04000124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001209041 2001-07-10
PCT/JP2002/006904 WO2003006019A1 (fr) 2001-07-10 2002-07-08 Composition medicinale destinee au traitement de la cystite interstitielle

Publications (1)

Publication Number Publication Date
MXPA04000124A true MXPA04000124A (es) 2004-05-21

Family

ID=19044753

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000124A MXPA04000124A (es) 2001-07-10 2002-07-08 Composicion farmaceutica para la terapia de cistitis intersticial.

Country Status (19)

Country Link
US (2) US7335668B2 (es)
EP (1) EP1405638B1 (es)
JP (1) JP4174673B2 (es)
KR (1) KR100874815B1 (es)
CN (1) CN1270708C (es)
AT (1) ATE497765T1 (es)
AU (1) AU2002315814B2 (es)
BR (1) BR0210873A (es)
CA (1) CA2449922C (es)
CY (1) CY1112600T1 (es)
DE (1) DE60239134D1 (es)
DK (1) DK1405638T3 (es)
ES (1) ES2359719T3 (es)
MX (1) MXPA04000124A (es)
PL (1) PL208138B1 (es)
PT (1) PT1405638E (es)
RU (1) RU2290929C2 (es)
WO (1) WO2003006019A1 (es)
ZA (1) ZA200309632B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005075474A1 (ja) * 2004-02-09 2007-10-11 アステラス製薬株式会社 コハク酸ソリフェナシン含有組成物
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
US7820690B2 (en) * 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
RU2359670C2 (ru) 2004-03-25 2009-06-27 Астеллас Фарма Инк. Композиция солифенацина или его соли для использования в твердом препарате
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
CA2571133C (en) 2004-07-15 2011-04-19 Japan Tobacco Inc. Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
JPWO2006090759A1 (ja) * 2005-02-25 2008-07-24 アステラス製薬株式会社 ソリフェナシン含有医薬
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
JP4614084B2 (ja) * 2005-07-25 2011-01-19 アステラス製薬株式会社 キヌクリジン誘導体含有医薬組成物
JP4086895B2 (ja) 2005-12-28 2008-05-14 日本たばこ産業株式会社 ３，４−ジヒドロベンゾオキサジン化合物及びバニロイド受容体１型（ｖｒ１）活性阻害剤
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
TWI482629B (zh) * 2008-07-01 2015-05-01 Tobishi Pharmaceutical Co 下泌尿道疾病治療劑及下泌尿道症狀改善劑
MD4025C2 (ro) * 2009-08-25 2010-10-31 Владимир КАРАУШ Remediu pentru tratamentul prostatitei şi hiperplaziei prostatei
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
DK1475099T4 (da) * 1997-07-15 2014-05-19 Univ Colorado Anvendelse af botulinum-toksin til behandling af urininkontinens
KR100375003B1 (ko) * 1998-11-05 2003-03-06 다이호야쿠힌고교 가부시키가이샤 배뇨장애 치료제
WO2001013918A1 (en) * 1999-08-23 2001-03-01 H. Lundbeck A/S Treatment of urinary incontinence

Also Published As

Publication number Publication date
BR0210873A (pt) 2004-06-22
US7335668B2 (en) 2008-02-26
CN1270708C (zh) 2006-08-23
EP1405638B1 (en) 2011-02-09
PL208138B1 (pl) 2011-03-31
RU2290929C2 (ru) 2007-01-10
KR100874815B1 (ko) 2008-12-19
WO2003006019A1 (fr) 2003-01-23
DK1405638T3 (da) 2011-04-18
EP1405638A4 (en) 2006-04-12
AU2002315814B2 (en) 2007-05-31
KR20040029358A (ko) 2004-04-06
EP1405638A1 (en) 2004-04-07
RU2004103746A (ru) 2005-03-27
JP4174673B2 (ja) 2008-11-05
JPWO2003006019A1 (ja) 2004-10-28
ES2359719T3 (es) 2011-05-26
ATE497765T1 (de) 2011-02-15
CN1527708A (zh) 2004-09-08
CA2449922C (en) 2008-11-25
PL366731A1 (en) 2005-02-07
ZA200309632B (en) 2004-12-22
US20090105298A1 (en) 2009-04-23
CY1112600T1 (el) 2016-02-10
CA2449922A1 (en) 2003-01-23
PT1405638E (pt) 2011-04-06
DE60239134D1 (de) 2011-03-24
US20040138252A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
MXPA04000124A (es) Composicion farmaceutica para la terapia de cistitis intersticial.
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
GB0108592D0 (en) Therapeutic agents
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
HK1043947A1 (en) Use of biochemical substances in the manufacture of a medicament for preventing and treating health conditions caused by constriction of smooth musclecells in organs of the human body
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
EP1631297A4 (en) TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1440689A3 (en) Treatment of neurotic disorders
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
WO2004018044A8 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FG Grant or registration